Leflunomide for chronic musculoskeletal graft versus host disease following allogeneic hematopoietic stem cell transplant

Bone Marrow Transplant. 2020 Feb;55(2):467-469. doi: 10.1038/s41409-019-0545-x. Epub 2019 May 14.

Authors

Sachin Punatar¹, Aniket Mohite¹, Anant Gokarn¹, Lingaraj Nayak¹, Avinash Bonda¹, Kartthik Shanmugam¹, Kalasekhar Vijaysekharan¹, Navin Khattry²

Affiliations

¹ HSCT unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Kharghar, Navi Mumbai, 410210, India.
² HSCT unit, Department of Medical Oncology, Tata Memorial Centre, ACTREC, Kharghar, Navi Mumbai, 410210, India. [email protected].

PMID: 31089281
DOI: 10.1038/s41409-019-0545-x

No abstract available

Publication types

Letter

MeSH terms

Graft vs Host Disease* / drug therapy
Graft vs Host Disease* / etiology
Hematopoietic Stem Cell Transplantation*
Humans
Leflunomide
Transplantation, Homologous

Substances

Leflunomide